
Article 1 
Regulation (EC) No 903/2009 is amended as follows:

((1)) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
((2)) In the Annex to Regulation (EC) No 903/2009, in the second column ‘Name of the holder of authorisation’, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Article 2 
Implementing Regulation (EU) No 373/2011 is amended as follows:

((1)) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
((2)) In the Annex to Implementing Regulation (EU) No 373/2011, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Article 3 
Implementing Regulation (EU) No 374/2013 is amended as follows:

((1)) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
((2)) In the Annex to Implementing Regulation (EU) No 374/2013, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Article 4 
Implementing Regulation (EU) No 1108/2014 is amended as follows:

((1)) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
((2)) In the Annex to Implementing Regulation (EU) No 1108/2014, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Article 5 
Existing stocks of the additive, premixtures and compound feed containing the additive, which are in conformity with the provisions applying before the date of entry into force of this Regulation may continue to be placed on the market and used until they are exhausted.
Article 6 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation is binding in its entirety and directly applicable in all Member States.Done at Brussels, 23 June 2017.
For the Commission
The President
Jean-Claude JUNCKER